DOC — Healthpeak Properties, Inc.

The tape is mixed: August 2026 Q2 results beat with adjusted FFO of $0.46 vs. $0.43 consensus, full-year FFO guidance was raised to $1.73-$1.77, and the $2.1B Brookfield outpatient-medical JV was a positive strategic move. However, the 30-year Treasury yield above 5.3% pressures REIT multiples, the analyst consensus is Hold with a $22.25 target, and the stock sits only modestly below its 52-week high of $22.95.

Revenue has compounded steadily from roughly $556M in Q3 2023 to $771.6M in Q2 2026, with YoY growth accelerating to 11.1% in Q2 2026. GAAP earnings are noisy due to impairments, divestitures, and the Janus Living IPO: Q3 2025 was -$0.17, Q1 2026 was $0.28, and Q2 2026 was $0.08. Operating margin was 16.2% in Q2 2026 versus 18.9% a year earlier, but that is within the recent 15%-20% band and not a clear deterioration. The underlying trend is moderate growth, helped by outpatient medical and lab demand, not a structural decline or a classic cyclical trough.

On trailing GAAP P/E of 60.6x and forward EPS of $0.413, DOC looks expensive, but REITs should be judged on FFO: 2026E FFO midpoint of $1.75 puts the stock at roughly 12.1x forward FFO, which is reasonable for a healthcare REIT. Price-to-sales of 4.96x is below the 5-year average of 6.16x, P/B is 1.87x, and the dividend yield is about 5.9%. The label 'Cheap vs. its own history' is fair: not a deep value stock, but not expensive on the metrics that matter for a REIT.

As of 2026-08-27, the $21.22 price is pricing in roughly 12.1x 2026E FFO, which is neither heroic nor distressed. The market is paying a normal multiple for steady, rate-sensitive cash flows and management's raised guidance. If Healthpeak hits the $1.73-$1.77 FFO range and the Brookfield JV accretively recycles capital, there is modest room to re-rate toward $22.50-$23.00; if long rates keep climbing, the multiple could compress toward 11x despite in-line earnings.

As of 2026-08-27, RSI stood at 48.55, price was +0.21% versus the 20-day SMA, -1.15% versus the 50-day SMA, and +14.62% versus the 200-day SMA. That is a neutral momentum read: the medium-term uptrend is intact, but the stock is range-bound near-term and neither overbought nor oversold. For entry timing, there is no technical urgency; a pullback toward the 50-day or a decisive close above $22.95 would give a cleaner signal.

• Elevated long-term Treasury yields, with the 30-year above 5.3%, pressure REIT valuations and raise refinancing costs.
• Healthcare real estate demand remains supported by an aging demographic, especially outpatient medical and seniors housing.
• Lab demand is tied to biotech and pharma funding cycles; positive leasing spreads could stall if early-stage funding tightens.
• REIT capital flows and sector rotation mean rate-sensitive equities can sell off even when company-specific fundamentals improve.
• Healthcare reimbursement and operator credit risk are ongoing watch items for medical office and senior housing tenants.

• Q3 2026 earnings in late October/early November 2026, the first full quarter reflecting the Brookfield JV and post-Janus-Living portfolio.
• A sustained decline in long-term Treasury yields would likely drive multiple expansion across REITs, including DOC.
• Further capital recycling, asset sales, or deployment of the $100M buyback program from the Brookfield transaction.
• Continued occupancy gains and positive cash leasing spreads in the Lab and Outpatient Medical portfolios.
• The September 2026 ex-dividend date and monthly payout, which reinforce income demand for the stock.

• Higher-for-longer rates: long-term debt of $9.28B and a debt-to-equity ratio of 1.32x make the balance sheet sensitive to refinancing costs.
• GAAP earnings volatility: net income swung to -$117M in Q3 2025, and negative gross profit in some recent quarters signals impairment or accounting noise.
• Heavy capex/investment periods can turn FCF negative, as in Q2 2026, when capex of $883.6M produced -$522.5M FCF.
• Lab demand is exposed to biotech funding cycles; a slowdown would hit occupancy and same-store NOI growth.
• Broad analyst sentiment is only Hold, so there is limited sell-side momentum to push the stock meaningfully higher without a new catalyst.

Healthpeak is a solidly run healthcare REIT with 11% revenue growth, a raised FFO guide, and a ~5.9% yield, but at $21.22 it is not dramatically undervalued. My fair-value estimate is about $22.50, so the stock offers modest upside plus income while waiting for rates to cooperate. It is a reasonable hold/accumulate for income-oriented investors, not a high-conviction buy.

Fair value of $22.50 is derived by applying a 12.9x P/FFO multiple to the midpoint of 2026 FFO guidance ($1.75), a modest premium to the current 12.1x implied multiple justified by 11% revenue growth, the Brookfield JV, and a ~5.9% dividend yield; this also cross-checks to about a 5.4% normalized dividend yield on the $1.22 annualized dividend.